Mokari Atabak: insider trades.
Mokari Atabak reported 23 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 17 sales ($12.7M), across 1 company.
- Transactions
- 23
- Purchases (P)
- 0
- Sales (S)
- 17
- Companies
- 1
- Name as filed
- Mokari Atabak
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Corcept Therapeutics Inc (CORT) | Officer · Chief Financial Officer | 23 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-02 | Corcept Therapeutics Inc | F | 102 | $113.38 | 16,304 | Form 4 |
| 2026-09-01 | Corcept Therapeutics Inc | A | 138 | $0 | 16,406 | Form 4 |
| 2026-09-01 | Corcept Therapeutics Inc | A | 138 | $113.38 | 16,268 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 7,089 | $116.96 | 38,284 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 8,267 | $117.93 | 30,017 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 4,783 | $118.73 | 25,234 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 8,103 | $119.95 | 17,131 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 1,001 | $120.67 | 16,130 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 8,956 | $106.96 | 82,974 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 400 | $108.46 | 82,574 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 2,202 | $110.03 | 80,372 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 600 | $110.95 | 79,772 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 4,700 | $113.18 | 75,072 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 15,477 | $114.96 | 59,595 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 14,222 | $115.87 | 45,373 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | M | 80,000 | $23.06 | 96,130 | Form 4 |
| 2026-07-30 | Corcept Therapeutics Inc | S | 4,200 | $105.54 | 91,930 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | M | 15,833 | $19.26 | 31,963 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 101 | $89.43 | 16,130 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 3,520 | $88.3 | 16,231 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 28,460 | $87.89 | 19,751 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | S | 7,919 | $86.78 | 48,211 | Form 4 |
| 2026-07-15 | Corcept Therapeutics Inc | M | 24,167 | $23.06 | 56,130 | Form 4 |
Questions
What stock did Mokari Atabak buy or sell?
Mokari Atabak reported 23 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 17 sales ($12.7M), across 1 company.
Is Mokari Atabak the same person as other filers with this name?
This page covers SEC CIK 1678419 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/mokari-atabak-1678419.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.